Literature DB >> 12937141

Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer.

Oliver Stoeltzing1, Wenbiao Liu, Niels Reinmuth, Fan Fan, Alexander A Parikh, Corazon D Bucana, Douglas B Evans, Gregg L Semenza, Lee M Ellis.   

Abstract

Activation of the insulin-like growth factor-I receptor (IGF-IR) was recently shown to modulate angiogenesis by up-regulating the expression of vascular endothelial growth factor (VEGF). We hypothesized that inhibiting IGF-IR function would inhibit angiogenesis and growth of pancreatic cancer in vivo and sought to identify major signaling pathways regulated by IGF-IR in pancreatic cancer cells. Human pancreatic cancer cells (L3.6pl) were stably transfected with a dominant-negative form of IGF-IR (IGF-IR DN) or an empty vector (pcDNA). In vitro, IGF-IR DN cells exhibited a decrease in both constitutive and inducible phosphorylation of IGF-IR and Erk1/2. Constitutive expression of nuclear hypoxia-inducible factor-1alpha and secreted VEGF (P < 0.01) protein levels also were significantly lower in IGF-IR DN cells than in pcDNA cells. In vivo, IGF-IR inhibition led to decreases in pancreatic tumor volume and weight, vessel density, and tumor cell proliferation (P < 0.01 for all) and increases in tumor cell apoptosis (P < 0.02). Our results suggest that autocrine activation of the IGF-IR system significantly affects VEGF expression and angiogenesis in human pancreatic cancer. Thus, IGF-IR may be a valid target in the treatment of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12937141      PMCID: PMC1868239          DOI: 10.1016/s0002-9440(10)63460-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  56 in total

1.  Receptors and ligands for autocrine growth pathways are up-regulated when pancreatic cancer cells are adapted to serum-free culture.

Authors:  L O Murphy; Y H Abdel-Wahab; Q J Wang; J A Knezetic; J Permnert; J Larsson; A M Hollingsworth; T E Adrian
Journal:  Pancreas       Date:  2001-04       Impact factor: 3.327

2.  In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice.

Authors:  C J Bruns; M T Harbison; H Kuniyasu; I Eue; I J Fidler
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

3.  The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer.

Authors:  S A Ahmad; W Liu; Y D Jung; F Fan; M Wilson; N Reinmuth; R M Shaheen; C D Bucana; L M Ellis
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

4.  Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

Authors:  C J Bruns; C C Solorzano; M T Harbison; S Ozawa; R Tsan; D Fan; J Abbruzzese; P Traxler; E Buchdunger; R Radinsky; I J Fidler
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

5.  Expression of insulin-like growth factor-1 receptor in human colorectal cancer.

Authors:  A Hakam; T J Yeatman; L Lu; L Mora; G Marcet; S V Nicosia; R C Karl; D Coppola
Journal:  Hum Pathol       Date:  1999-10       Impact factor: 3.466

6.  Regulation of vascular endothelial growth factor expression by insulin-like growth factor-I in endometrial adenocarcinoma cells.

Authors:  L Bermont; F Lamielle; S Fauconnet; H Esumi; A Weisz; G L Adessi
Journal:  Int J Cancer       Date:  2000-01-01       Impact factor: 7.396

7.  Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.

Authors:  L E Smith; W Shen; C Perruzzi; S Soker; F Kinose; X Xu; G Robinson; S Driver; J Bischoff; B Zhang; J M Schaeffer; D R Senger
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

8.  AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells.

Authors:  S Tanno; S Tanno; Y Mitsuuchi; D A Altomare; G H Xiao; J R Testa
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

9.  Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.

Authors:  C J Bruns; M T Harbison; D W Davis; C A Portera; R Tsan; D J McConkey; D B Evans; J L Abbruzzese; D J Hicklin; R Radinsky
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

10.  Insulin-like growth factor I and transforming growth factor alpha as autocrine growth factors in human pancreatic cancer cell growth.

Authors:  E Ohmura; M Okada; N Onoda; Y Kamiya; H Murakami; T Tsushima; K Shizume
Journal:  Cancer Res       Date:  1990-01-01       Impact factor: 12.701

View more
  59 in total

1.  Diabetes and pancreatic cancer.

Authors:  Donghui Li
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 2.  Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis.

Authors:  André L Mihaljevic; Christoph W Michalski; Helmut Friess; Jörg Kleeff
Journal:  Langenbecks Arch Surg       Date:  2010-03-18       Impact factor: 3.445

Review 3.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Hypoxia inducible factor-1 mediates effects of insulin on pancreatic cancer cells and disturbs host energy homeostasis.

Authors:  Feng Wang; Shu Shun Li; Ralf Segersvärd; Lisa Strömmer; Karl-Gösta Sundqvist; Jan Holgersson; Johan Permert
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

5.  Activating transcription factor 3 promotes colon cancer metastasis.

Authors:  Zhi-Yong Wu; Zheng-Mao Wei; Sheng-Jie Sun; Jing Yuan; Shun-Chang Jiao
Journal:  Tumour Biol       Date:  2014-05-24

6.  Does diabetes mellitus affect presentation, stage and survival in operable pancreatic cancer?

Authors:  Clement L K Chia; Anthea Y S Lee; Vishal G Shelat; Saleem Ahmed; Sameer P Junnarkar; Winston W L Woon; Jee-Keem Low
Journal:  Hepatobiliary Surg Nutr       Date:  2016-02       Impact factor: 7.293

7.  Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression.

Authors:  Young Wha Koh; Dok Hyun Yoon; Cheolwon Suh; Hee Jeong Cha; Jooryung Huh
Journal:  Int J Exp Pathol       Date:  2015-04-27       Impact factor: 1.925

8.  Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review.

Authors:  Ming Yin; Xiaoxiang Guan; Zhongxin Liao; Qingyi Wei
Journal:  Am J Transl Res       Date:  2009-01-30       Impact factor: 4.060

9.  Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system.

Authors:  Oliver Stoeltzing; Wenbiao Liu; Fan Fan; Christine Wagner; Kathrin Stengel; Ray J Somcio; Niels Reinmuth; Alexander A Parikh; Daniel J Hicklin; Lee M Ellis
Journal:  Cancer Lett       Date:  2007-10-22       Impact factor: 8.679

10.  Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer.

Authors:  Chunhui Zhang; Li Hao; Liang Wang; Yichuan Xiao; Hailiang Ge; Zhenya Zhu; Yunbao Luo; Yi Zhang; Yanyun Zhang
Journal:  BMC Cancer       Date:  2010-05-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.